 |
|
|
Merge eFilm Signs Agreement
with Zimmer For Incorporation of Orthopedic Templates
in eFilm Workstation™. Clinical use of eFilm Workstation
enhanced with pre-operative planning templates for orthopedic
surgeons.
Milwaukee, WI, November 12, 2002
Milwaukee, WI, November 12, 2002 – Merge eFilm
(Nasdaq: MRGE), a medical image and information management
solutions provider, today announced the expanded development
of eFilm Workstation for its first speciality market,
orthopedics. Merge eFilm has signed an agreement with
Zimmer to include their orthopedic templates as an optional
feature in its widely-utilized eFilm Workstation, software
that is used throughout the world to view and manipulate
digital medical images, supporting a filmless environment.
eFilm Workstation allows the surgeons to access the
patient’s medical images digitally, and to utilize
image manipulation tools and the Zimmer templates for
surgical preplanning without use of traditional films
and acetate templates. The Zimmer Orthopedic Templates
assist orthopedic surgeons in pre-operative planning
for artificial joint replacements.
"We are pleased to be a partner in providing the
best possible tools for Merge eFilm’s orthopedic
customers," said Walt D. Harrison, Vice President
of Sales and Marketing, Zimmer Inc. "Merge eFilm
is known throughout the world for its innovative software-based
alternative to PACS, and their development of orthopedic-centric
tools will accelerate that sector’s move towards
a digital model."
"The Merge eFilm product innovation model centers
on software-based, enterprise wide digital image and
information management solutions," said Rich Linden,
President and CEO of Merge eFilm. "We will continue
to expand the clinical depth of the end-user software
applications like eFilm Workstation, to optimize its
use across the healthcare enterprise and among all clinical
specialties. Common, world-wide use of eFilm Workstation
among all specialties continues to be an important goal
of the company, along with providing the same set of
image viewing and diagnostic tools for all clinicians
involved in the care of the patient."
Zimmer, based in Warsaw, Indiana, is a global leader in
the design, development, manufacturing and marketing of
orthopedic reconstructive implants and fracture management
products. The company provides a broad range of joint
replacement and fracture management products, as well
as other products for orthopedic and general surgery.
In an independent survey of U.S. orthopedic surgeons,
Zimmer was ranked as the number one company in 10 of 11
categories related to products and service and the number
one company overall serving the joint replacement surgeon.
For additional information, go to www.zimmer.com.
|
Attn: Beth Frost-Johnson
Merge Healthcare
6737 West Washington St.
Suite 2250
Milwaukee, WI 53214
|
|
|
|
|
|
| Except for the historical information herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. When used in this press release, the words “will,” “believes,” “intends,” “anticipates,” “expects” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, the forward-looking statements based on a number of factors, including, but not limited to, the uncertainty created by, the adverse impact on relationships with customers, potential customers, suppliers and investors potentially resulting from, and other risks associated with, the changes in the Company’s senior management; costs, risks and effects of the investigation by the Audit Committee of the Board of Directors; the impact of the restatement of financial statements of the Company and other actions that may be taken or required as a result of such restatement; the Company's inability to timely file reports with the Securities and Exchange Commission; risks associated with the Company's inability to meet the requirements of The NASDAQ Stock Market for continued listing, including possible delisting; costs, risks and effects of legal proceedings and investigations, including the informal, non-public inquiry being conducted by the Securities and Exchange Commission and class action, derivative, and other lawsuits; risks in product and technology development, market acceptance of new products and continuing product demand, the impact of competitive products and pricing, ability to integrate acquisitions, changing economic conditions, credit and payment risks associated with end-user sales, dependence on major customers, dependence on key personnel, and other risk factors detailed in the Company’s filings with the Securities and Exchange Commission. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements contained herein to reflect future events, developments, or changed circumstances, or for any other reason.
|
|
|
